Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: label-supported indication/mechanism/LDL-lowering are accurate, but several grapefruit-related mechanistic, risk, and outside-of-label citrus-food statements are unsupported or overreaching relative to the provided label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
1 INDICATIONS AND USAGE (lipid-altering therapy with LIPITOR as adjunct in hypercholesterolemia)
Lipitor works by inhibiting cholesterol production in the liver.
12.1 Mechanism of Action (selective competitive inhibitor of HMG-CoA reductase; converts to mevalonate precursor of sterols)
Lipitor reduces low-density lipoprotein (LDL) cholesterol.
12.1 Mechanism of Action (states LIPITOR reduces LDL-C)
Grapefruit juice contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
7.2 Grapefruit Juice (components inhibit CYP 3A4; can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption)
Rhabdomyolysis/myopathy is a serious adverse reaction class matter discussed in the label (rare cases reported).
5.1 Skeletal Muscle (rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported)
Unsupported Statements
Grapefruit contains furanocoumarins.
No furanocoumarins mention in the provided label excerpts.
Furanocoumarins inhibit the activity of the enzyme CYP3A4.
Mechanistic details (furanocoumarins) not supported by provided label excerpts.
CYP3A4 is responsible for metabolizing a wide range of medications, including Lipitor.
Label excerpt indicates importance of CYP3A4 metabolism of LIPITOR but does not state CYP3A4 metabolizes a 'wide range' of medications.
When grapefruit is consumed, furanocoumarins bind to CYP3A4, reducing its activity.
No furanocoumarins or 'binding' mechanism described in the provided label excerpts.
Reducing CYP3A4 activity allows more Lipitor to remain in the bloodstream.
Label supports increased plasma concentrations, but does not explicitly describe 'remain in the bloodstream' as the mechanism.
Consuming grapefruit juice while taking Lipitor can lead to respiratory failure.
Not supported by provided label excerpts.
Consuming grapefruit juice while taking Lipitor can lead to death.
Not supported by provided label excerpts.
A case report described rhabdomyolysis after consuming grapefruit juice while taking Lipitor.
No case-report statement appears in the provided label excerpts.
The risk of rhabdomyolysis with grapefruit while taking Lipitor is small but not zero.
Quantitative risk framing not supported by provided label excerpts.
Avoiding grapefruit altogether is recommended for people taking Lipitor who are concerned about grapefruit.
Provided label excerpt (7.2) discusses increased concentrations with excessive consumption; it does not recommend avoiding grapefruit altogether.
Lemons are generally considered safe to consume with Lipitor.
No citrus-food safety claims for lemons appear in the provided label excerpts.
Limes are unlikely to interact with Lipitor.
No citrus-food safety/interaction claims for limes appear in the provided label excerpts.
Oranges, tangerines, and clementines are described as safe alternatives to grapefruit that can be consumed with Lipitor.
No such alternative-food safety/interaction claims appear in the provided label excerpts.
Rhabdomyolysis is characterized by muscle breakdown.
Not explicitly defined in the provided label excerpts.
Contradictions
Important Omissions
Any label-anchored thresholding or quantification about grapefruit only being problematic with excessive grapefruit juice consumption (>1.2 liters/day) is not explicitly carried over in the response.
Importance:
Moderate
Label-supported counseling/monitoring concepts around muscle symptoms and when to consider CPK/withholding/discontinuation are not reflected in the response claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported overreaching claims (mechanism via furanocoumarins, respiratory failure/death, specific case report, and absolute grapefruit avoidance; plus unlabelled citrus safety statements) could mislead risk perception and behavior relative to the label-supported interaction content (CYP3A4 inhibition and increased atorvastatin exposure with excessive grapefruit juice).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple grapefruit-related mechanistic and downstream risk assertions are not supported by the provided label excerpts, and additional citrus-food safety claims are entirely outside the supplied label content.
Suggested Improvement
Restrict grapefruit interaction statements to label-supported language in 7.2 (CYP3A4 inhibition components; increased atorvastatin plasma concentrations, especially with excessive consumption >1.2 L/day). Remove or qualify unlabelled mechanistic details (furanocoumarins/binding), remove unlabelled outcomes (respiratory failure/death), and omit unsubstantiated citrus food safety claims unless present in the prescribing information.